🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "major milestone" in the effort against increasingly resistant strains of the infection, according to health experts.

A Worldwide Public Health Issue

Gonorrhoea infections are on the rise around the world, with data suggesting over 82 million infections per year. Notably increased rates are observed in the African continent and countries within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. Within England, cases have hit a all-time high, while figures across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of novel therapies for gonorrhoea is an significant and necessary development in the context of rising global incidence, the spread of superbugs and the highly restricted therapeutic options presently on offer.”

Medical experts are deeply concerned about the increase in treatment-resistant strains. The World Health Organization has designated it as a "priority pathogen". Recent surveillance showed that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Drugs Secure Clearance

Zoliflodacin, also known as Nuzolvence, was approved by the US FDA in December for treating gonorrhoea. This infection can lead to serious health problems, including infertility. Researchers believe that focused deployment of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, created by the drugmaker GSK, gained clearance in concurrent days. This medication, which is employed against UTIs, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin stemmed from a innovative non-profit model for drug creation. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to develop it.

“This authorization represents a significant shift in the management of highly resistant gonorrhoea, which previously has been evolving faster than medical innovation.”

Testing Data and Global Access

As per results released by a major medical journal, the new drug successfully treated more than 90% of genital gonorrhoea infections. This establishes an equal footing with the current standard treatment, which uses an injection and a pill. The study involved nearly 1,000 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, the non-profit has the ability to make available and distribute the drug in a wide range of low-income and middle-income countries.

Medical professionals directly involved have voiced optimism. Having a one-pill regimen of this kind is hailed as a "revolutionary step" for public health efforts. This is considered essential to lessen the impact of the disease for people and to halt the transmission of untreatable gonorrhoea globally.